Suresh Durgam

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

György Németh, I. Laszlovszky, Pál Czobor et al. · The Lancet · 2017 · 336 citations

Predominant Negative Symptoms, Psychiatry, Psychotic Disorder +8

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression

Suresh Durgam, Willie Earley, Alan Lipschitz et al. · American Journal of Psychiatry · 2015 · 202 citations · Full text

Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials

Eduard Vieta, Suresh Durgam, Kaifeng Lu et al. · European Neuropsychopharmacology · 2015 · 191 citations · Full text

Psychiatry, Mean Change, Medicine +14

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder

Eduard Vieta, Willie Earley, Maria Victoria Burgess et al. · International Clinical Psychopharmacology · 2018 · 187 citations · Full text

Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia

John M. Kane, Stephen R. Zukin, Yao Wang et al. · Journal of Clinical Psychopharmacology · 2015 · 176 citations

Drug Safety, Psychoactive Drug, Psychiatry +14